Special Issues

Application of Multi-omics Analysis in Cancer Immunotherapy

Submission Deadline: 30 December 2024 View: 4 Submit to Special Issue

Guest Editors

Dr. Yutian Zou, Sun Yat-Sen University Cancer Center, China. E-mail: zouyt@sysucc.org.cn

Dr. Zui Pan, University of Texas at Arlington, United States. E-mail: zui.pan@uta.edu

Dr. Zhi Tian, University of South Florida, United States. E-mail: ztian@usf.edu

Dr. Jindong Xie, Sun Yat-Sen University Cancer Center, China. E-mail: xiejd1@sysucc.org.cn


According to statistics from the World Health Organization, cancer is regarded as the leading cause of death around the world and continues to remain an issue in the 21st century. Recently, immune checkpoint therapy has been proven an effective strategy in various advanced solid tumors and has rapidly become a hotspot in the research of antitumor drugs. Immune checkpoint therapy targeting programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) has emerged as an effective strategy for various cancers, yielding significant improvement in disease-free and overall survival of patients with cancer. However, some kinds of cancer were regarded as immune-quiescent tumors, which means only a small proportion of patients would benefit from immunotherapy in addition to a high rate of severe adverse events. With the development of multi-omics analyses, exploring a new strategy to target the tumor microenvironment factors might be possible for cancer immunotherapy.


The scope covers all aspects of the immunotherapies targeting the tumor microenvironment of different cancers, including but not limited to new strategies to enhance immunotherapy effects, immunotherapy resistance in cancer, personalized immunotherapy for cancer, biomarkers for immunotherapy response, bioinformatics and machine learning approaches in efficacy prediction; non-coding RNAs for immunotherapy of cancer, lipid metabolism, exosomes, immunotherapeutic drug delivery system, mechanism of immune escape in cancer, novel immune cells or molecules in the cancer microenvironment.


We invite to this Special Issue the submission of scientific articles or reviews that focus on the application of multi-omics analyses in tumor immunotherapy.


Immunotherapy; Multi-omics; Biomarker; Drug response; Molecular mechanism; Tumor microenvironment; Machine-learning method; Bioinformatics

Published Papers

  • Open Access


    Metochalcone induces senescence-associated secretory phenotype via JAK2/STAT3 pathway in breast cancer

    Oncology Research, Vol.32, No.5, pp. 943-953, 2024, DOI:10.32604/or.2023.044775
    (This article belongs to the Special Issue: Application of Multi-omics Analysis in Cancer Immunotherapy)
    Abstract Breast and lung cancers are the leading causes of mortality and most frequently diagnosed cancers in women and men, respectively, worldwide. Although the antitumor activity of chalcones has been extensively studied, the molecular mechanisms of isoliquiritigenin analog 2', 4', 4-trihydroxychalcone (metochalcone; TEC) against carcinomas remain less well understood. In this study, we found that TEC inhibited cell proliferation of breast cancer BT549 cells and lung cancer A549 cells in a concentration-dependent manner. TEC induced cell cycle arrest in the S-phase, cell migration inhibition in vitro, and reduced tumor growth in vivo. Moreover, transcriptomic analysis revealed that TEC More >

    Graphic Abstract

    Metochalcone induces senescence-associated secretory phenotype via JAK2/STAT3 pathway in breast cancer

  • Open Access


    The DMRTA1-SOX2 positive feedback loop promotes progression and chemotherapy resistance of esophageal squamous cell carcinoma

    Oncology Research, Vol.31, No.6, pp. 887-897, 2023, DOI:10.32604/or.2023.030184
    (This article belongs to the Special Issue: Application of Multi-omics Analysis in Cancer Immunotherapy)
    Abstract Esophageal squamous cell carcinoma (ESCC) is among the most prevalent causes of cancer-related death in patients worldwide. Resistance to immunotherapy and chemotherapy results in worse survival outcomes in ESCC. It is urgent to explore the underlying molecular mechanism of immune evasion and chemoresistance in ESCC. Here, we conducted RNA-sequencing analysis in ten ESCC tissues from cisplatin-based neoadjuvant chemotherapy patients. We found that DMRTA1 was extremely upregulated in the non-pathologic complete response (non-pCR) group. The proliferation rate of esophageal squamous carcinoma cells was markedly decreased after knockdown of DMRTA1 expression, which could increase cisplatin sensitivity in More >

  • Open Access


    Comprehensive analysis of the role of immune-related PANoptosis lncRNA model in renal clear cell carcinoma based on RNA transcriptome and single-cell sequencing

    Oncology Research, Vol.31, No.4, pp. 543-567, 2023, DOI:10.32604/or.2023.029563
    (This article belongs to the Special Issue: Application of Multi-omics Analysis in Cancer Immunotherapy)
    Abstract The high immune infiltration and heterogeneity of the microenvironment in clear cell renal cell carcinoma (ccRCC) result in the variability of prognosis and clinical response. While PANoptosis has strong immunogenicity and is worthy of further study. In this study, data from The Cancer Genome Atlas database was used to obtain immune-related PANoptosis lncRNAs with prognostic value. Subsequently, the role of these lncRNAs in cancer immunity, progression and the therapeutic response was analyzed, and a new prediction model was constructed. Additionally, we further explored the biological value of PANoptosis-related lncRNAs using single-cell data from the Gene… More >

Share Link